Pfizer Inc. Q2 FY26 Results — Earnings Call Analysis
Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹1.5L Cr
- Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by pipeline advancements and launched/acquired products. - Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by a strong pipeline and launched/acquired products.
From Pfizer Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.
Price
₹26.14
Market Cap
₹1.5L Cr
P/E Ratio
19.7
Revenue Rank
Margin Rank
How does Pfizer Inc. rank in Pharmaceuticals?
Compare Pfizer Inc. against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 3- →Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by pipeline advancements and launched/acquired products.
- →Growth momentum comes from oncology assets, obesity therapies, vaccines (RSV, pediatric, maternal immunization), and primary care franchises.
- →The obesity market, especially in China and emerging markets with high prevalence, is a significant growth driver.
- →Launch and acquired products are already growing 22% operationally with $3.1 billion Q1 revenue and expected continued growth.
- →Vaccines maintain strong market leadership with over 60% market share in key categories.
- →Despite near-term losses from expiring patents, new products and pipeline assets with multiple risk-adjusted readouts support long-term top-line growth.
- →AI integration is anticipated to accelerate R&D efficiency and commercial execution, further supporting sustained growth.
- →Pfizer aims to defend and grow existing patient bases and penetrate new patient segments for franchise expansion.
📈 Profitability & Margins
Rank 3- →Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by a strong pipeline and launched/acquired products.
- →First quarter 2026 adjusted operating margin was strong at 38%, above pre-pandemic levels, reflecting effective cost management.
- →Adjusted diluted earnings per share (EPS) in Q1 2026 was $0.75, exceeding expectations.
- →Full-year 2026 guidance reaffirmed with revenues in the range of $59.5 billion to $62.5 billion and adjusted diluted EPS between $2.80 and $3.00.
- →Growth is supported by solid contributions from key brands and ongoing R&D investments.
- →Legal developments (e.g., VYNDAMAX settlement) and manufacturing optimizations improve cash flow visibility and support capital allocation.
- →Focus remains on managing near-term patent expirations (LOEs) and investing to enable durable long-term growth.
🏗️ Capital Expenditure Plans
Yes- →Pfizer continues to invest significantly in R&D, with $2.5 billion invested in internal R&D in Q1 2026, focusing on oncology, obesity, and other key therapeutic areas.
- →They are making targeted investments today to drive revenue growth later in the decade and beyond.
- →The company is investing in AI integration across R&D, commercial, manufacturing, and enterprise functions to accelerate innovation and improve decision-making.
- →Manufacturing optimization programs are ongoing, aiming for $700 million in savings in 2026, with $175 million realized in Q1.
- →Business development capacity stands at approximately $7 billion, primarily for pipeline support and opportunistic acquisitions.
- →Capital allocation includes reinvesting in the business with focus on strategic growth, maintaining dividends, and preserving optionality for share repurchases and value-enhancing actions.
- →Pfizer is pursuing pipeline prioritization and portfolio management to support long-term growth.
💰 Fundraising & Capital Structure
No information- →Pfizer’s capital allocation strategy currently focuses on reinvesting in R&D and business development to drive long-term value.
- →There is no explicit mention of immediate plans for new fundraising through debt or equity in the provided text.
- →The company has $7 billion in business development (BD) capacity, boosted by proceeds from the sale of its stake in Vive.
- →With recent legal developments giving more confidence in cash flow, share repurchase considerations may increase, but no direct plans for new debt or equity issuance are stated.
- →Leverage is expected to remain around current levels or slightly higher during the transition period due to upcoming loss of exclusivity (LOE) headwinds.
- →Pfizer made its final tax repatriation payment in April 2026, indicating no recent large financing needs.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
Others in Pharmaceuticals this season
- Elanco Animal Health Incorporated (Q2 FY26)
Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S
- Axsome Therapeutics, Inc. (Q2 FY26)
Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from
- Jazz Pharmaceuticals plc (Q2 FY26)
Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo
- Viatris Inc. (Q2 FY26)
Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7
Frequently Asked Questions
What were Pfizer Inc. Q2 FY26 results?
- Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by pipeline advancements and launched/acquired products. - Pfizer expects a high single-digit 5-year revenue CAGR starting in 2029, driven by a strong pipeline and launched/acquired products.
What is Pfizer Inc. share price analysis?
Pfizer Inc. currently shows a below-average growth signal. The stock trades at a P/E of 19.7 with a market cap of $148,983. Investors should review the full earnings analysis for detailed insights.
Is Pfizer Inc. planning capital expenditure?
- Pfizer continues to invest significantly in R&D, with $2.5 billion invested in internal R&D in Q1 2026, focusing on oncology, obesity, and other key therapeutic areas.
Keep Pfizer Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.